An observational analysis showed a long-term OS benefit with Orca-T in adult patients undergoing allogeneic transplantation for hematologic malignancies.
|Videos|June 22, 2017
Dr. Ansell on FDA Approval of Subcutaneous Rituximab in Select Blood Cancers
Author(s)Stephen M. Ansell, MD, PhD
Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses the FDA approval of subcutaneous rituximab (Rituxan) in patients with select hematologic malignancies.
Advertisement
Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses the FDA approval of subcutaneous rituximab (Rituxan) in patients with select hematologic malignancies.
Advertisement
Related to this article
Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, discusses recent CLL approvals, BTK and BCL-2 inhibitor safety, and individualizing frontline therapy.
The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Mosunetuzumab plus lenalidomide met the CELESTIMO trial's primary end point, improving PFS in relapsed/refractory follicular lymphoma.
A PET-guided, nivolumab-based regimen produced promising response rates in advanced-stage classical Hodgkin lymphoma.
Bexobrutideg produced responses across lines of therapy in chronic lymphocytic leukemia/small lymphocytic lymphoma.
The FDA set a target action date of June 29, 2027, for bezuclastinib's NDA in advanced systemic mastocytosis, backed by APEX trial data.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
Etentamig Improves Response and PFS vs Standard Therapies in Triple-Class Exposed Relapsed/Refractory Myeloma
3
Tegavivint Plus Osimertinib Shows Early Activity in First-Line EGFR-Mutated NSCLC
4
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
5